Tredje AP fonden Lowers Stake in Pfizer Inc. (NYSE:PFE)

Tredje AP fonden lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 274,098 shares of the biopharmaceutical company’s stock after selling 14,427 shares during the period. Tredje AP fonden’s holdings in Pfizer were worth $7,272,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Retirement Wealth Solutions LLC purchased a new position in Pfizer in the 4th quarter valued at approximately $26,000. Rialto Wealth Management LLC purchased a new position in Pfizer in the 4th quarter valued at approximately $26,000. Gladius Capital Management LP boosted its position in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares during the period. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer in the 4th quarter valued at approximately $28,000. Finally, Noble Wealth Management PBC purchased a new position in Pfizer in the 4th quarter valued at approximately $31,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Trading Down 0.4 %

NYSE PFE opened at $25.60 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market cap of $145.08 billion, a PE ratio of 18.16, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The firm’s fifty day moving average is $26.26 and its two-hundred day moving average is $27.17.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 earnings per share. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday. Wolfe Research assumed coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.